Option chain shows key data for 's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for .

 (OTC:CIGBF) Stock, Option Chain

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for blarcamesine (ANAVEX&#xAE;2-73), an investigational drug for the treatment of Alzheimer's disease. The Company is looking forward to working with the EMA.
Blarcamesine is an orally once daily administered small molecule for the potential treatment of patients with Alzheimer's disease.

Government

News

Regulations

AVXL

Anavex's Alzheimer's Drug Blarcamesine Accepted for Review by European Regulators

Piper Sandler analyst Sumeet Mody maintains Enfusion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENFN#NYSE">ENFN</a>) with a Neutral and raises the price target from $10 to $11.5.

Price Target

Analyst Ratings

ENFN

Piper Sandler Maintains Neutral on Enfusion, Raises Price Target to $11.5

Barclays analyst Brandt Montour maintains Carnival (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) with a Overweight and raises the price target from $31 to $32.

Barclays Maintains Overweight on Carnival, Raises Price Target to $32

Institutional adoption of cryptocurrencies is now &#8220;for real this time,&#8221; according to Messari's 2025 crypto theses report, which highlights the growing presence of traditional finance <a href="https://www.benzinga.com/24/12/42516240/the-doors-have-been-blown-off-how-bitcoin-etfs-are-reshaping-investment-strategies">in digital assets</a>.
What Happened: The <a href="https://messari.io/report/the-crypto-theses-2025">report</a> cites approvals of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42526592/bitcoin-ethereum-etfs-see-688m-net-inflows-analysts-target-124000">exchange-traded funds</a> (ETFs), increasing involvement from major financial players and the expanding role of tokenized assets as evidence that institutional adoption is firmly underway.
Messari emphasizes that institutional engagement has shifted beyond ETFs, with asset issuance, <a href="https://www.benzinga.com/money/how-do-stablecoins-make-money">stablecoin development</a> and broader <a href="https://www.benzinga.com/money/what-is-blockchain">blockchain applications</a> gaining momentum.
&#8220;The institutions are here &#8211; this time for real. The approval of the BTC and ETH ETFs has legitimized the asset class and made it more accessible to both retail and institutional allocators,&#8221; the report states.
The report also highlights other key developments reshaping the crypto industry, including the rise of <a href="https://www.benzinga.com/money/depin-crypto-coins">decentralized physical infrastructure networks (DePIN)</a>, which saw significant growth in sectors like compute, energy and mobility.
The market capitalization of DePIN projects surged by 132% year-over-year, showcasing their role in bridging blockchain infrastructure with real-world applications.
Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) emerged as another standout performer, achieving notable gains in 2024 driven by advancements like the Firedancer upgrade and its dominance in decentralized exchange volumes. 
Messari points to Solana's ability to deliver high throughput and lower costs, positioning it as a growing competitor to Ethereum.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42526592/bitcoin-ethereum-etfs-see-688m-net-inflows-analysts-target-124000">Bitcoin, Ethereum ETFs See $688M Net Inflows, Analysts Target $124,000</a>
Meanwhile, Ethereum continues to play a central role as Layer-2 scaling solutions gain traction, improving network efficiency and throughput. 
The report notes that while Ethereum remains foundational, Layer-2 rollups have outpaced Layer-1 activity, reflecting the platform's evolving role amid market competition.
Messari also explores the expanding Bitcoin ecosystem, where institutional inflows and increasing utility are bolstering Bitcoin&#8217;s recognition as a macroeconomic hedge. 
The convergence of <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42512673/ai-cryptocurrencies-surge-208-to-61-5-billion-market-cap-in-2024-these-were-the-top-perfor">AI and crypto</a> is another trend identified in the report, with decentralized AI projects like Bittensor (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TAO</a>) driving innovation and enabling new use cases for blockchain technology.
The report further highlights renewed innovation across DeFi, stablecoins,and consumer apps, reflecting broader momentum in the crypto market.
What&#8217;s Next: With institutional participation now firmly entrenched and multiple sectors experiencing growth, Messari concludes that the macro environment for crypto adoption has entered a new phase.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42514820/ftx-reorganization-plan-set-for-january-3-distributions-to-commence-within-60-days">FTX Reorganization Plan Set For January 3, Distributions To Commence Within 60 Days</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

$TAO

Institutional Crypto Adoption 'For Real This Time,' Says Messari

Piper Sandler analyst Crispin Love upgrades GCM Grosvenor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCMG#NASDAQ">GCMG</a>) from Neutral to Overweight and raises the price target from $12.5 to $14.

Upgrades

GCMG

Piper Sandler Upgrades GCM Grosvenor to Overweight, Raises Price Target to $14

ParaZero Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRZO#NASDAQ">PRZO</a>) (the "Company or "ParaZero"), an aerospace company focused on safety systems for defense and commercial drones and urban air mobility aircrafts, previously announced that it received an order for its SafeAir&#x2122; systems from a significant distributor specializing in drones and drone technology in Australia.&nbsp;
This order, which was announced earlier this month, highlights ParaZero's accelerating growth in the Australian drone market, fuelled by its recent regulatory approvals and strategic collaborations. As the adoption of drones expands across industries, ParaZero's cutting-edge solutions reflect its commitment to set and advance the standards for drone safety, empowering operators to meet the highest safety standards while advancing innovation.
ParaZero's SafeAir&#x2122; systems are designed to autonomously detect flight anomalies and deploy a parachute, minimizing risks and ensuring safety in complex drone operations. <a href="https://www.globenewswire.com/Tracker?data=QoObMc4XRrrTqiWs0k8_qO33cD3CMq0UvGwl51vxxlcF0mDpN2lA2yia9Fg0kzzpjkjtx1ULSLRYg97m8BnoM-_KDkr4C8FWkZnJ0Fo3Afe3QEEy2MHQUSaCmJnu3vIMQMHgQFX8s1gLOrA0JfZutc7InXJYaM_AO6MjXTLDTCKYJW4TC4Bjnou7wDXqyJGb8dfAL2ReLtF64U7q5b6NNdmvIV4K2OEdeapaOF01ry-A9DGJuCO-24Ym2SJs3vsi4OcFF__8Zd9f4EyU4oqgI70ATWS2jrfZ-ZA01LLIaFO0_iBRsHhMiMMYuGqIxpskYlgg8298TCuoKcTU_MF0ZeyZ_67jPSjMQob_TkkXxzL3giAM1je56cBK7o2c_l1ukdziVbHhM1RL5CHnB-R_LjvqhuTfPXlQPdJ64UMkEHygwebuUrfv5AeqwVpnZCSw">In October 2023, ParaZero's technology received approval from the Civil Aviation Safety Authority (CASA),</a> enabling commercial drone flights over populated areas and near people—a landmark regulatory milestone in Australia.
Collaborating with prominent local distributors has been central to ParaZero's success in the region. By leveraging these partnerships, ParaZero has made its CASA-approved safety systems widely accessible, empowering operators to conduct advanced and safe drone missions.

PRZO

ParaZero Expands Australian Market with Drone Safety Tech Order

TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) ("TeraWulf" or the "Company"), a leading owner and operator of vertically integrated, next-generation digital infrastructure powered by predominantly zero-carbon energy, today announced the signing of long-term data center lease agreements with Core42, a G42 company specializing in sovereign cloud, AI infrastructure, and digital services.
Under the data center lease agreements, TeraWulf will deliver over 70 megawatts (MW)1 of turn-key data center infrastructure to host Core42's deployment at the Lake Mariner facility in Upstate New York. The infrastructure will be released for production in phases between Q1 and Q3 2025.
TeraWulf will customize the data halls to support Core42's GPU clusters, which will feature state-of-the-art Dell Integrated Rack Scalable Solutions, the <a href="https://www.globenewswire.com/Tracker?data=8y3F9NNOZ4U380vPkbI8fe67XMhPiVwXtKFjU9eKri1zk3MMWLeb-6czzf0hIjok1UMddGJxZKnvd5PmTGKCS1iap9rsJ6TlsURqvPDiEUIoX3gfCHBlldx0d4Es1MDcS6en9sCc4MuJoo2v55gc5W53FbkTyYxZ9S5xyyVC8lQcGF0H986d-yCxlkPIAhXl">Dell IR5000</a>. These integrated racks include direct liquid cooled Dell PowerEdge XE9680L GPU servers and will come online in phases.

WULF

TeraWulf Partners with Core42 to Provide 70 MW Data Center for AI Infrastructure

HUB Cyber Security Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUBC#NASDAQ">HUBC</a>) ("HUB" or the "Company"), a leader in cybersecurity and advanced data fabric solutions, has successfully restructured $7 million of its secured debt with United Mizrahi Tefahot Bank ("UMTB") under a settlement agreement signed on December 19, 2024 between HUB and UMTB (the "Agreement"). The Agreement represents over 60% of HUB's secured debt, through its wholly-owned subsidiary Comsec Ltd., and reflects the Company's commitment to address key financial obligations in its ongoing efforts to settle or extend most of its outstanding debt to achieve financial stability and confidence in its growth trajectory.
Under the Agreement, payments are deferred until June 2025, aligning with HUB's expected free cash flow generation. This milestone enhances liquidity and enables the Company to focus on scaling operations and delivering shareholder value. Furthermore, HUB is in advanced negotiations to refinance the remainder of its secured debt, with completion expected in the first quarter of 2025.

HUBC

HUB Cyber Security Restructures $7M Debt to Boost Financial Stability

<a href="https://www.ft.com/content/77bd9117-0a2d-4bd7-9248-4dd288f695a4" title="https://www.ft.com/content/77bd9117-0a2d-4bd7-9248-4dd288f695a4">https://www.ft.com/content/77bd9117-0a2d-4bd7-9248-4dd288f695a4</a>

Fintech news covering the emerging Financial Technology services sector

Fintech

Rumors

Financial Times Reported Meta Plans To Add Displays To Its Ray-ban Smart Glasses As Soon As Next Year

Castle Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>), a company improving health through innovative tests that guide patient care, today provided an update on its test currently in development for use in patients diagnosed with moderate-to-severe atopic dermatitis (AD) who are seeking systemic treatment. Based on preliminary data from the Company's ongoing prospective development and validation study, Castle's pipeline test has shown potential to identify a subset of patients with AD who have an increased likelihood to achieve a super response to targeted therapies, indicated by a 90% or greater reduction in Eczema Area and Severity Index (EASI) score (EASI90) at three months. Assuming successful validation, the Company currently expects to launch its pipeline test by the end of 2025.

CSTL

Castle Biosciences Advances Test to Predict Super Response in Atopic Dermatitis

RAPT Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing novel therapies for patients with significant unmet needs in inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 100,000,000 shares of common stock at a purchase price of $0.85 per share and (ii) to certain investors, in lieu of shares of common stock, pre-funded warrants to purchase up to 76,452,000 shares of common stock at a price per pre-funded warrant of&nbsp;$0.8499, for gross proceeds of approximately $150.0 million. The private placement is expected to close on or about December 27, 2024, subject to the satisfaction of customary closing conditions. The pre-funded warrants will have an exercise price of&nbsp;$0.0001&nbsp;per share of common stock, be immediately exercisable and remain exercisable until exercised in full.
The private placement was led by The Column Group and TCGX, with participation by new and existing investors including BVF Partners LP, Deep Track Capital, Foresite Capital, Medicxi, OrbiMed, Perceptive Advisors, Redmile Group and RTW Investments.
Net proceeds from the private placement are expected to fund the research and development of the Company's pipeline and for general corporate purposes.

Offerings

RAPT

RAPT Therapeutics To Raise $150M in Private Placement to Advance Drug Pipeline

Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>), a leading global provider of payments and financial services technology, today announced it has entered into a definitive agreement to acquire Payfare Inc. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PAY#TSX">PAY</a>), a provider of program management solutions with a particular focus on new economy workforces. The transaction is subject to obtaining shareholder and court approvals and other customary closing conditions and is expected to close in the first half of 2025.
This acquisition complements the embedded finance solutions of Fiserv with card program management, a white-label consumer app, and a microservices orchestration layer. These Payfare offerings, combined with the strengths of Fiserv in processing, bank ledgers and integrated value-added services, enhance the Fiserv solution in embedded banking, payments and lending and help meet needs of large enterprises and financial institutions.
"Payfare has built a reputation as an innovator in workforce payments for gig-economy companies," said Frank Bisignano, Chairman, President and Chief Executive Officer of Fiserv. "Together, we can accelerate the delivery of embedded finance solutions for all of our clients, empowering their next chapter of success. We look forward to welcoming the talented Payfare team to Fiserv."
"Joining Fiserv is a tremendous opportunity for Payfare," said Marco Margiotta, CEO and Founding Partner of Payfare. "We recognize that Fiserv gives us enhanced scale and technology which better positions us to serve a growing number of large organizations and deliver a modern digital experience."

TSX:PAY

Fiserv to Acquire Payfare, Strengthening Gig Economy Payment Solutions

Traws Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced progress in the development of its investigational one-dose influenza (flu) investigational therapy, tivoxavir marboxil for treatment of H5N1 bird flu.
"The spread of avian influenza in wild and domestic animal populations including mammals, brings increasing risk for adaptation to humans and subsequent spread in the population" said Robert R. Redfield, MD, Chief Medical Officer for Traws Pharma and former Director of the U.S. Centers for Disease Control and Prevention (CDC). "Bird flu is an occupational hazard for poultry and dairy workers. With increasing numbers of human infections and recent reports of severe cases, we should be alert to the rising potential for epidemic or pandemic spread of bird flu."
"In laboratory testing, tivoxavir marboxil inhibited multiple isolates of highly pathogenic avian influenza H5N1. We evaluated the effects of drug treatment in mice exposed to human H5N1, where the virus was isolated from a dairy worker exposed to infected cattle," said C. David Pauza, PhD, Chief Science Officer for Traws Pharma. "Oral treatment with tivoxavir marboxil after the virus infection resulted in complete survival and lung virus levels below the limit of quantitation1. This result is highly encouraging for future clinical development of tivoxavir marboxil for treating human H5N1 influenza."

TRAW

Traws Pharma Advances One-Dose Bird Flu Treatment with Results

D. Boral Capital analyst Jason Kolbert initiates coverage on Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Buy rating and announces Price Target of $36.

Initiation

OMER

D. Boral Capital Initiates Coverage On Omeros with Buy Rating, Announces Price Target of $36

HSDT

Helius Secures First PoNS System Sale To Veterans Affairs, Advancing MS Gait Therapy For U.S. Veterans

Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Epioxa&#x2122; (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, a progressive, sight-threatening corneal disease.
"The NDA submission for Epioxa represents an important milestone for our company as it brings us one step closer in being able to provide keratoconus patients and the ophthalmic community with the first FDA-approved, non-invasive corneal cross-linking drug therapy that does not require removal of the corneal epithelium, the outermost layer of the front of the eye," said Thomas Burns, Glaukos chairman and chief executive officer. "We look forward to working closely with the FDA in their pending review process and continue to believe Epioxa, which is designed to reduce procedure times, improve patient comfort and shorten recovery time,represents a potentially meaningful advancement in the treatment paradigm for patients suffering from keratoconus."

GKOS

Glaukos Seeks FDA Approval for Non-Invasive Keratoconus Therapy Epioxa

D. Boral Capital analyst Jason Kolbert initiates coverage on Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) with a Buy rating and announces Price Target of $32.

CMPX

D. Boral Capital Initiates Coverage On Compass Therapeutics with Buy Rating, Announces Price Target of $32

<a href="https://www.globenewswire.com/Tracker?data=qew_wVgWX_vHMlpArWea1LUZ93LCUsjxRNhS0gW4nUvbaprdKQ1PdFmGa3vCzNXjouFUlqeGoDRDZlMf_MKav_jkyfiuD-G65HTm5nXYF2WEgZPWJFIcGG4aEdYMP3-MjMi9mK4qNU5cmG94yIIqK_1104sUJTOwVIabqjF4hxvAiQuCKTQSDZi6czOJnNlA">Immunocore Holdings plc (NASDAQ:</a><a href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announces that the first patient has been dosed in the Phase 1 trial of IMC-P115C (PRAME-HLE-A02), which is a half-life extended ImmTAC candidate.
IMC-P115C was developed to improve patient convenience by reducing the frequency of treatment administration. It is Immunocore's first half-life extended candidate, and sixth ImmTAC candidate to enter the clinic. IMC-P115C is a PRAME x CD3 ImmTAC bispecific protein, with the same CD3 and targeting the same HLA-A&#x2A;02:01 PRAME (PReferentially expressed Antigen in MElanoma) peptide as brenetafusp.

IMCR

Immunocore Advances Half-Life Extended Cancer Treatment with First Patient Dosed

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.laserphotonics.com%2F&amp;esheet=54170279&amp;newsitemid=20241223663585&amp;lan=en-US&amp;anchor=Laser+Photonics+Corporation&amp;index=1&amp;md5=3715c11cb515309fd94c03d1671c25d0">Laser Photonics Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>) (LPC), a leading global developer of industrial laser systems for cleaning and other material processing applications, announced today that it received an order from the Cooper Nuclear Station (CNS), Nebraska's largest single-unit generator providing clean and reliable electricity.
"Laser cleaning technology is rapidly gaining ground as a highly effective alternative to hazardous surface preparation methods," said John Armstrong, Executive Vice President of Laser Photonics. "LPC is serving a growing number of clients in the nuclear energy sector, and we are thrilled that Cooper Nuclear entrusted us in providing its team with innovative laser-powered equipment."
The <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Flaserphotonics.com%2Flaser-systems%2Fhandheld-laser-cleaning-systems%2Fcleantech-commercial-roughening-laser-3010&amp;esheet=54170279&amp;newsitemid=20241223663585&amp;lan=en-US&amp;anchor=CleanTech+CR-3010&amp;index=3&amp;md5=648ce4909d9533b57b919a5cb1725e6b">CleanTech CR-3010</a>, acquired by CNS, is a commercial-grade handheld continuous wave fiber laser machine for surface preparation. It effectively removes contaminants and coatings off various surfaces during maintenance and production processes, and it has demonstrated its capability to blast off radioactive particles along with unwanted material. Paired with a fume extractor, the system turns into an irreplaceable power tool for the regular maintenance of equipment and infrastructure.
CNS, operated by the Nebraska Public Power District (NPPD), plans to use the CleanTech CR-3010 for paint and rust removal in the pre-weld preparation of valves, pipes and steel plates across plant equipment.

LASE

Laser Photonics Secures Nuclear Sector Deal with Cooper Station for Laser Tech

Brookline Capital analyst Leah Rush initiates coverage on Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy rating.

Comments

(CIGBF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga